Medikit (7749) Q1 2025 earnings summary

Executive summary

• Revenue for the six months ended September 30, 2024, increased 4.1% year-over-year to ¥11,285 million, while operating income declined 2.5% to ¥2,220 million and net income attributable to shareholders fell 3.2% to ¥1,278 million.

• Domestic sales growth was driven by strong performance in dialysis and intravenous catheter products, while overseas sales were impacted by the end of a major distribution contract.

• The company revised its mid-term management plan to adapt to changing market conditions and continues to focus on product innovation and expansion.

Financial highlights

• Gross profit for the period was ¥4,296 million, with a gross margin of 38.1%, down from 40.7% year-over-year.

• Operating cash flow was ¥1,408 million, a 42.3% decrease year-over-year, mainly due to higher tax payments.

• Capital expenditures increased, with ¥1,654 million spent on tangible fixed assets, reflecting ongoing factory expansion.

• EPS for the period was ¥86.40, up from ¥78.64 in the prior year.

Outlook and guidance

• Full-year revenue is forecast at ¥22,385 million, up 2.4% year-over-year, but operating income and net income are expected to decline by 11.0% and 10.6%, respectively.

• No changes have been made to the previously announced full-year guidance.

• Annual dividend forecast is ¥90 per share, up from ¥80 in the previous year.